HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026
HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 — AGC Biologics has announced a new partnership with Teikoku Seiyaku Co., Ltd. to provide process development and GMP manufacturing services for KTP-001, an investigational recombinant human matrix metalloproteinase-7 (rhMMP-7) therapy being developed to treat lumbar disc herniation. The agreement strengthens AGC Biologics’ position as a leading global contract development and manufacturing organization (CDMO) while advancing Teikoku Seiyaku’s efforts to deliver innovative and less invasive treatment options for spinal disorders.
The collaboration will utilize AGC Biologics’ international microbial manufacturing network, beginning with initial cell bank creation activities at the company’s Microbial Center of Excellence in Heidelberg, Germany, before transitioning to its Chiba, Japan facility for process development and Good Manufacturing Practice (GMP) production to support future clinical trials. The partnership highlights the growing importance of globally integrated CDMO services in accelerating biologic drug development and ensuring supply chain flexibility for next-generation therapies.
AGC Biologics Expands Global CDMO Leadership
Under the agreement, AGC Biologics will leverage more than four decades of microbial manufacturing expertise to support development of KTP-001, a novel biologic candidate designed to provide a non-surgical treatment approach for patients suffering from lumbar disc herniation. The condition affects millions of people worldwide and is a major cause of chronic lower back pain, disability, and reduced quality of life.
Teikoku Seiyaku selected AGC Biologics because of its proven track record in microbial process development and its globally connected manufacturing infrastructure spanning Asia, Europe, and North America. According to Teikoku Seiyaku executives, the partnership provides both technical expertise and operational security necessary to support future clinical and commercial manufacturing activities.
Advertisement
Dr. Hiroyuki Kubo, Director and Executive Officer at Teikoku Seiyaku, emphasized that AGC Biologics’ collaborative approach and global capabilities were key factors in the decision. He noted that the partnership is expected to play an important role in advancing the company’s innovative therapy toward clinical development and ultimately improving patient outcomes for individuals suffering from spinal disorders.
Novel rhMMP-7 Therapy Targets Lumbar Disc Herniation
The investigational therapy KTP-001 utilizes recombinant human matrix metalloproteinase-7 technology designed to address lumbar disc herniation through a minimally invasive biological mechanism. The therapy aims to offer an alternative to conventional surgical interventions by targeting damaged disc tissue while potentially reducing recovery time and treatment-associated complications.
AGC Biologics stated that its Heidelberg facility will initially focus on establishing robust microbial cell banking systems and upstream development activities before transferring the project to the company’s Chiba manufacturing site for large-scale process optimization and GMP manufacturing for clinical trial supply.
Company executives highlighted the importance of maintaining continuity across international development sites to ensure manufacturing consistency, regulatory compliance, and accelerated timelines for emerging biologic therapies. AGC Biologics also noted that its global microbial network allows pharmaceutical and biotechnology companies to reduce development risk and secure reliable manufacturing support amid evolving global healthcare and geopolitical conditions.
Global Manufacturing Networks Drive Biopharma Innovation
The collaboration between AGC Biologics and Teikoku Seiyaku reflects broader trends within the global biopharmaceutical manufacturing sector, where companies increasingly rely on specialized CDMO partners to accelerate complex biologic drug development programs. Demand for microbial manufacturing capabilities has continued rising as developers pursue recombinant proteins, enzyme therapies, and precision biologics for chronic and degenerative diseases.
AGC Biologics currently operates microbial manufacturing facilities in Japan, Germany, Denmark, and the United States, making it one of the few CDMOs capable of supporting integrated global biologics production across multiple continents. Industry analysts believe such international manufacturing flexibility is becoming increasingly critical for ensuring resilient pharmaceutical supply chains and supporting future commercial scale-up activities.
The partnership also demonstrates growing industry investment in advanced biologic therapies targeting orthopedic and spinal conditions, areas where minimally invasive treatment approaches continue attracting significant clinical and commercial interest. With clinical development activities now advancing, both companies aim to support the future availability of innovative therapies capable of improving quality of life for patients with chronic spinal disorders.
Source: AGC Biologics press release
